Omicron Scare: Does booster dose really neutralizes COVID-19's new variant?
India TV NewsAn international team of researchers recently studied the sensitivity of Omicron to antibodies compared with the currently dominant Delta variant. In a new study supported by the European Union's Health Emergency Preparedness and Response Authority, scientists from the Institut Pasteur and the Vaccine Research Institute, in collaboration with KU Leuven, Orleans Regional Hospital, Hospital Europeen Georges Pompidou and Inserm, studied the sensitivity of Omicron to antibodies compared with the currently dominant Delta variant. The isolated virus was immediately sent to scientists at the Institut Pasteur, where therapeutic monoclonal antibodies and serum samples from people who had been vaccinated or previously exposed to SARS-CoV-2 were used to study the sensitivity of the Omicron variant. "This study shows that the Omicron variant hampers the effectiveness of vaccines and monoclonal antibodies, but it also demonstrates the ability of European scientists to work together to identify challenges and potential solutions. While KU Leuven was able to describe the first case of Omicron infection in Europe using the Belgian genome surveillance system, our collaboration with the Institut Pasteur in Paris enabled us to carry out this study in record time," commented Emmanuel Andre, co-last author of the study, a Professor of Medicine at KU Leuven and Head of the National Reference Laboratory and the genome surveillance network for COVID-19 in Belgium.